FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283276031> ?p ?o ?g. }

• W4283276031 endingPage "2229" @default.
• W4283276031 startingPage "2218" @default.
• W4283276031 abstract "GWN323, an agonistic human anti-GITR (glucocorticoid-induced TNFR-related protein) IgG1 antibody, was studied clinically as an immuno-oncology therapeutic agent. A model-based minimum anticipated biological effect level (MABEL) approach integrating in vitro and in vivo data informed dose selection for the first-in-human (FIH) study. Data evaluated included pharmacokinetics (PK) of DTA-1.mIgG2a (mouse surrogate GITR antibody for GWN323), target-engagement pharmacodynamic (PD) marker soluble GITR (sGITR), tumor shrinkage in Colon26 syngeneic mice administered with DTA-1.mIgG2a, cytokine release of GWN323 in human peripheral blood mononuclear cells, and GITR binding affinity. A PK model was developed to describe DTA-1.mIgG2a PK, and its relationship with sGITR was also modeled. Human GWN323 PK was predicted by allometric scaling of mouse PK. Based on the totality of PK/PD modeling and in vitro and in vivo pharmacology and toxicology data, MABEL was estimated to be 3-10 mg once every 3 weeks (Q3W), which informed the starting dose selection of the FIH study. Based on tumor kinetic PK/PD modeling of tumor inhibition by DTA-1.mIgG2a in Colon26 mice and the predicted human PK of GWN323, the biologically active dose of GWN323 was predicted to be 350 mg Q3W, which informed the dose escalation of the FIH study. GWN323 PK from the FIH study was described by a population PK model; the relationship with ex vivo interleukin-2 release, a target-engagement marker, was also modeled. The clinical PK/PD modeling data supported the biological active dose projected from the translational PK/PD modeling in a learn and confirm paradigm of model-informed drug development of GWN323." @default.
• W4283276031 created "2022-06-23" @default.
• W4283276031 creator A5002382843 @default.
• W4283276031 creator A5013176295 @default.
• W4283276031 creator A5015764873 @default.
• W4283276031 creator A5016087125 @default.
• W4283276031 creator A5020583341 @default.
• W4283276031 creator A5034913283 @default.
• W4283276031 creator A5041031002 @default.
• W4283276031 date "2022-07-19" @default.
• W4283276031 modified "2023-09-26" @default.
• W4283276031 title "Model‐informed drug development for immuno‐oncology agonistic <scp>anti‐GITR</scp> antibody <scp>GWN323</scp>: Dose selection based on <scp>MABEL</scp> and biologically active dose" @default.
• W4283276031 cites W1202139631 @default.
• W4283276031 cites W1548780175 @default.
• W4283276031 cites W1602071727 @default.
• W4283276031 cites W2026426963 @default.
• W4283276031 cites W2074642772 @default.
• W4283276031 cites W2096305848 @default.
• W4283276031 cites W2097074641 @default.
• W4283276031 cites W2097726328 @default.
• W4283276031 cites W2099738485 @default.
• W4283276031 cites W2145066420 @default.
• W4283276031 cites W2149294990 @default.
• W4283276031 cites W2151937278 @default.
• W4283276031 cites W2154280336 @default.
• W4283276031 cites W2244578404 @default.
• W4283276031 cites W2509587195 @default.
• W4283276031 cites W2554268745 @default.
• W4283276031 cites W2624341173 @default.
• W4283276031 cites W2887389018 @default.
• W4283276031 cites W2894508341 @default.
• W4283276031 cites W2899058237 @default.
• W4283276031 cites W2906252243 @default.
• W4283276031 cites W2910555254 @default.
• W4283276031 cites W3070640115 @default.
• W4283276031 cites W3083349647 @default.
• W4283276031 cites W3115217375 @default.
• W4283276031 cites W3192736776 @default.
• W4283276031 cites W4239710358 @default.
• W4283276031 cites W4283276031 @default.
• W4283276031 cites W98240345 @default.
• W4283276031 doi "https://doi.org/10.1111/cts.13355" @default.
• W4283276031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35731955" @default.
• W4283276031 hasPublicationYear "2022" @default.
• W4283276031 type Work @default.
• W4283276031 citedByCount "2" @default.
• W4283276031 countsByYear W42832760312022 @default.
• W4283276031 countsByYear W42832760312023 @default.
• W4283276031 crossrefType "journal-article" @default.
• W4283276031 hasAuthorship W4283276031A5002382843 @default.
• W4283276031 hasAuthorship W4283276031A5013176295 @default.
• W4283276031 hasAuthorship W4283276031A5015764873 @default.
• W4283276031 hasAuthorship W4283276031A5016087125 @default.
• W4283276031 hasAuthorship W4283276031A5020583341 @default.
• W4283276031 hasAuthorship W4283276031A5034913283 @default.
• W4283276031 hasAuthorship W4283276031A5041031002 @default.
• W4283276031 hasBestOaLocation W42832760311 @default.
• W4283276031 hasConcept C111113717 @default.
• W4283276031 hasConcept C112705442 @default.
• W4283276031 hasConcept C116073593 @default.
• W4283276031 hasConcept C137061746 @default.
• W4283276031 hasConcept C150903083 @default.
• W4283276031 hasConcept C159654299 @default.
• W4283276031 hasConcept C185592680 @default.
• W4283276031 hasConcept C202751555 @default.
• W4283276031 hasConcept C203014093 @default.
• W4283276031 hasConcept C207001950 @default.
• W4283276031 hasConcept C26291073 @default.
• W4283276031 hasConcept C2778690821 @default.
• W4283276031 hasConcept C2780035454 @default.
• W4283276031 hasConcept C2908647359 @default.
• W4283276031 hasConcept C55493867 @default.
• W4283276031 hasConcept C57992300 @default.
• W4283276031 hasConcept C71924100 @default.
• W4283276031 hasConcept C86803240 @default.
• W4283276031 hasConcept C98274493 @default.
• W4283276031 hasConcept C99454951 @default.
• W4283276031 hasConceptScore W4283276031C111113717 @default.
• W4283276031 hasConceptScore W4283276031C112705442 @default.
• W4283276031 hasConceptScore W4283276031C116073593 @default.
• W4283276031 hasConceptScore W4283276031C137061746 @default.
• W4283276031 hasConceptScore W4283276031C150903083 @default.
• W4283276031 hasConceptScore W4283276031C159654299 @default.
• W4283276031 hasConceptScore W4283276031C185592680 @default.
• W4283276031 hasConceptScore W4283276031C202751555 @default.
• W4283276031 hasConceptScore W4283276031C203014093 @default.
• W4283276031 hasConceptScore W4283276031C207001950 @default.
• W4283276031 hasConceptScore W4283276031C26291073 @default.
• W4283276031 hasConceptScore W4283276031C2778690821 @default.
• W4283276031 hasConceptScore W4283276031C2780035454 @default.
• W4283276031 hasConceptScore W4283276031C2908647359 @default.
• W4283276031 hasConceptScore W4283276031C55493867 @default.
• W4283276031 hasConceptScore W4283276031C57992300 @default.
• W4283276031 hasConceptScore W4283276031C71924100 @default.
• W4283276031 hasConceptScore W4283276031C86803240 @default.
• W4283276031 hasConceptScore W4283276031C98274493 @default.
• W4283276031 hasConceptScore W4283276031C99454951 @default.
• W4283276031 hasIssue "9" @default.

• next